A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation

NCT04280081 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

77

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor
Medullary Thyroid Cancer

Interventions

DRUG: Selpercatinib

Sponsor

Eli Lilly and Company